All articles tagged with #amylin
Originally Published 2 months ago — by NBC News
Eli Lilly's experimental obesity drug, eloralintide, shows promising results in mid-stage trials, with significant weight loss and improved health markers, leading to plans for late-stage trials and potential as an alternative to existing therapies.
Originally Published 4 months ago — by bestlifeonline.com
Scientists have discovered new insights into the hormone amylin, which could lead to more effective weight-loss medications by better understanding its receptors, potentially speeding up the development of next-generation obesity drugs like amylin-based treatments currently in trials.
Originally Published 6 months ago — by STAT
Novo Nordisk's new amylin-based obesity drug, amycretin, shows significant weight loss in early trials, but similar efficacy across different doses and high side effects raise questions about optimal dosing strategies.
Originally Published 7 months ago — by statnews.com
Metsera's experimental drug targeting the amylin hormone showed promising results in early clinical trials, indicating potential for longer-lasting weight loss effects compared to existing weekly injections, highlighting a significant development in obesity treatment.
Originally Published 7 months ago — by statnews.com
Metsera's experimental obesity drug targeting amylin shows promising early results, with significant weight loss observed in initial trials, suggesting it may offer longer-lasting effects than current weekly injections.